Nautilus Biotechnology, Inc. (NAUT)
NASDAQ: NAUT · Real-Time Price · USD
2.320
-0.060 (-2.52%)
At close: Nov 13, 2026, 4:00 PM EST
2.250
-0.070 (-3.02%)
After-hours: Nov 13, 2026, 7:58 PM EST

Nautilus Biotechnology Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
25.3625.733128.925.9521.15
Research & Development
39.0741.1150.4847.2537.6729.35
Operating Expenses
64.4366.8481.4876.1563.6250.5
Operating Income
-64.05-66.84-81.48-76.15-63.62-50.5
Interest & Investment Income
5.587.8710.7812.555.820.33
Other Non Operating Income (Expenses)
-0.28-1.45-2.89-2.73-1.010.17
EBT Excluding Unusual Items
-58.75-60.42-73.58-66.33-58.81-50
Gain (Loss) on Sale of Investments
0.171.422.82.660.89-0.18
Gain (Loss) on Sale of Assets
------0.14
Pretax Income
-58.58-59-70.78-63.68-57.92-50.32
Net Income
-58.58-59-70.78-63.68-57.92-50.32
Net Income to Common
-58.58-59-70.78-63.68-57.92-50.32
Net Income Growth
------
Shares Outstanding (Basic)
12712612512512584
Shares Outstanding (Diluted)
12712612512512584
Shares Change
0.58%0.66%0.41%0.27%47.51%190.36%
EPS (Basic)
-0.46-0.47-0.56-0.51-0.46-0.60
EPS (Diluted)
-0.46-0.47-0.56-0.51-0.46-0.60
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-55.14-51.97-62.03-54.15-48.13-41.51
Free Cash Flow Per Share
-0.43-0.41-0.49-0.43-0.39-0.49
EBITDA
-62.76-65.08-79.42-74.3-62.4-49.48
D&A For EBITDA
1.291.752.061.851.221.02
EBIT
-64.05-66.84-81.48-76.15-63.62-50.5
SEC Filings: 10-K · 10-Q